Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability

Mechanism: Bempedoic acid works by inhibiting ACL in the cholesterol-synthesis pathway; since the activating enzyme is present only in the liver (not muscle), the risk of muscle-related side-effects is diminished.

Frontiers

Indication/Use Case: Particularly useful in patients who (a) are at elevated cardiovascular risk (primary prevention or secondary), (b) cannot tolerate statins or have suboptimal adherence, and (c) need further LDL-C reduction beyond statin (or in place of statin) therapy.

Efficacy:

~20-30% LDL-C lowering as monotherapy in statin-intolerant patients. PubMed

+1

Additional benefit when combined with other therapies (e.g., ~30-40% reduction when combined with ezetimibe).

medicinejournal.in

In primary-prevention high-risk patients intolerant of statins: LDL-C reduction ~21% and hs-CRP ~21% with meaningful reduction in cardiovascular events.

PubMed +1

Tolerability/Safety:

Lower risk of muscle symptoms compared to statins. PubMed

+1

Known adverse signals: hyperuricemia/gout, elevated liver enzymes, possibly increased creatinine/renal changes.

JAMA Network +1

Comparison with Statins:

Statins typically reduce LDL-C by much larger margins (30-50%+ depending on dose/intensity). Bempedoic acid's LDL-C reduction is more modest in comparison.

However, when looking at the risk reduction per unit LDL-C lowering, bempedoic acid appears to yield similar relative benefits as statins.

American College of Cardiology

+1

Clinical Implication: In patients with suboptimal statin use (due to intolerance, non-adherence, or contraindication), bempedoic acid offers a viable adjunct or alternative lipid-lowering strategy in the primary prevention setting.

Limitations:

Not a direct head-to-head trial of bempedoic acid versus statins in the scenario of suboptimal statin adherence.

Absolute reduction in LDL-C is lower than high-intensity statins, so expectations must be calibrated accordingly.

Long-term safety in wider populations continues to be monitored.

Cost and accessibility may vary by region; local cost-effectiveness needs evaluation.

Inclusion criteria

• Adults aged ≥40 years with no established ASCVD (no prior myocardial infarction, stroke, or acute coronary syndrome).
• Indicated for lipid-lowering therapy (LDL-C ≥130 mg/dL or 10-year ASCVD risk

≥7.5%).

• Documented history of poor statin adherence, defined as:

• Self-reported adherence <80% in the past 3 months, or
• Prior statin discontinuation for adverse effects documented in the medical record.
• Willingness to provide written informed consent. Exclusion Criteria
• Established ASCVD (secondary prevention).
• Severe hepatic impairment (ALT or AST >3× upper limit of normal).
• Severe renal impairment (eGFR <30 mL/min/1.73 m²).
• Pregnancy, breastfeeding, or women of childbearing potential not using contraception.
• Current or planned treatment with PCSK9 inhibitors, fibrates, or niacin.
• Known hypersensitivity to study drugs or excipients.